Safety
GLP-1s and Gastroparesis
Every one of these drugs delays gastric emptying — that is the mechanism, not a malfunction. The question worth answering is where the line sits between the intended effect and a condition you would not want.
This became a headline story and the coverage mostly collapsed two different things into one word. They are worth separating, because the distinction decides whether what you are experiencing is the treatment working or a problem.
The distinction
Delayed gastric emptying is a measurement: food leaves the stomach more slowly than it otherwise would. On a GLP-1, essentially everybody has this. It is the mechanism — it is a large part of why you feel full after four bites and why appetite falls — and it is described in what GLP-1s actually do.
Gastroparesis is a clinical diagnosis. It requires objectively delayed gastric emptying and a symptom burden — nausea, vomiting, early satiety, bloating, upper abdominal pain — in the absence of mechanical obstruction. It is a condition, not a measurement.
Almost everyone taking these drugs has the first. A small minority develop something that looks like the second, typically within the first 6 months.
What is actually known
The honest position has three parts.
Case reports and pharmacovigilance signals exist. People have developed severe, persistent gastroparesis-like illness on these medications, some requiring hospitalisation, and some with symptoms lasting after discontinuation. That is real and it should not be dismissed.
Attribution is genuinely difficult. Gastroparesis is substantially more common in people with type 2 diabetes and with obesity than in the general population, independent of any drug — diabetic gastroparesis is a long-recognised complication of longstanding diabetes. So the population being prescribed these drugs is already the population that gets it, and separating drug effect from background incidence requires careful study.
The absolute numbers appear low relative to how many people take these medications. That is reassurance about frequency, not about the individuals affected.
I am not going to tell you the question is settled. It is not, and how much follow-up exists across this class is set out in what we know about long-term safety.
Where the line is, practically
Here is the framing I use in clinic.
| Expected | Worth raising | Needs assessment |
|---|---|---|
| Full after a small meal | Fullness that stops you eating enough | Vomiting undigested food hours later |
| Mild nausea after a dose increase | Nausea persisting at a stable dose | Persistent vomiting, weight loss beyond expectation |
| Bloating, reflux | Reflux not settling with mechanical measures | Inability to keep fluids down |
| Reduced appetite | Appetite so reduced you cannot hit protein | Severe pain with vomiting |
The single symptom that should never be normalised is vomiting undigested food several hours after eating. That is retained gastric contents, and it is not the ordinary experience of this drug.
Nor is being unable to maintain hydration. That is the pathway to acute kidney injury described in sick day rules, and it does not become acceptable because the cause is the medication.
If you already have gastroparesis
Severe gastroparesis sits in the group of conditions requiring individual clinical assessment rather than a blanket rule — listed alongside prior pancreatitis and active gallbladder disease in who should not take a GLP-1.
In practice, most clinicians avoid these drugs in established symptomatic gastroparesis, and the reasoning is straightforward: adding a medication whose mechanism includes slowing gastric emptying to a stomach that already empties too slowly is a poor combination. Mild or well-controlled disease may be different, especially where the metabolic benefit is large.
That decision belongs with a gastroenterologist alongside your prescriber. It is not a form question, and it is one of the things a good prescriber screens for — see how to choose a GLP-1 prescriber.
What to do if you develop symptoms
Tell your prescriber rather than pushing through. Holding a dose for an extra 4–8 weeks resolves a large share of this. The most common good outcome is a dose reduction or a longer hold at the current dose, and titration is adjustable for exactly this reason.
Do not stop unilaterally without a plan, particularly with type 2 diabetes, and know that stopping does not produce immediate relief — the drug persists for 4–5 weeks, so improvement is measured in weeks. The arithmetic is in how long GLP-1s stay in your system.
Eat for a slow stomach in the meantime: smaller and more frequent, lower fat, softer textures, liquids separated from meals by 30 minutes, nothing lying down for 3 hours after eating. What to actually eat covers the structure.
Persistent symptoms months after stopping need proper assessment — gastric emptying study, and exclusion of mechanical obstruction — rather than continued waiting.
The procedure point, which is not optional
Delayed emptying means your stomach may not be empty after a standard pre-operative fast. That is an aspiration risk under anaesthesia, and it is the reason you tell anyone who is going to sedate you, unprompted, every time.
It applies to surgery, endoscopy, colonoscopy and dental work under sedation. For upper endoscopy there is a second problem — retained food obscures the view and procedures get abandoned. The full instruction, including why holding one weekly dose is not clearance, is in GLP-1s, surgery and procedures.
That is the one part of this article where the mechanism, rather than the rare complication, is what puts you at risk — and it applies to everybody taking these drugs, not to a minority.
Questions I get about this month
- Does Ozempic cause gastroparesis?
- It causes delayed gastric emptying, which is how it works — that is the intended pharmacology, and in most people it produces fullness and reduced appetite rather than illness. Whether it causes true gastroparesis, meaning a persistent symptomatic disorder of gastric motility, is less settled. Case reports and pharmacovigilance signals exist, and gastroparesis is also more common in people with type 2 diabetes and obesity independent of any drug, which makes attribution difficult.
- What is the difference between delayed gastric emptying and gastroparesis?
- Delayed emptying is a measurement — food leaves the stomach more slowly. Gastroparesis is a clinical diagnosis requiring both objectively delayed emptying and a symptom burden, in the absence of mechanical obstruction. Almost everyone on a GLP-1 has the first. Very few have the second. The distinction matters because the first is the treatment working and the second is a condition that needs assessment.
- Can I take a GLP-1 if I already have gastroparesis?
- Severe gastroparesis is one of the situations requiring individual clinical assessment rather than a general rule, and in practice most clinicians avoid these drugs in it — adding a medication that slows emptying to a stomach that already empties too slowly is a poor combination. Mild or well-controlled cases may be different, particularly where the metabolic benefit is substantial. This is a conversation with a gastroenterologist as well as your prescriber, not a decision from an intake form.
- Does gastroparesis from a GLP-1 go away after stopping?
- In most reported cases symptoms improve after discontinuation, but not immediately — semaglutide and tirzepatide persist for 4 to 5 weeks after the last dose, so the effect on gastric motility fades over weeks rather than days. Persistent symptoms months after stopping suggest something other than a straightforward drug effect and warrant proper gastroenterological assessment rather than continued waiting.
Sources
- 01Maselli DB, Camilleri M. Effects of GLP-1 and Its Analogs on Gastric Physiology in Diabetes Mellitus and Obesity. Advances in Experimental Medicine and Biology, 2021.
- 02Camilleri M, Kuo B, Nguyen L et al. ACG Clinical Guideline: Gastroparesis. American Journal of Gastroenterology, 2022.
- 03FDA prescribing information, Ozempic (semaglutide) injection.
- 04Joshi GP et al. American Society of Anesthesiologists Consensus-Based Guidance on Preoperative Management of Patients on Glucagon-Like Peptide-1 Receptor Agonists, 2023.
- 05Overgaard RV et al. Clinical Pharmacokinetics of Semaglutide. Clinical Pharmacokinetics, 2019.
Elise Hall, MD
Board-certified internist in Los Angeles, twenty-one years in practice. She writes about GLP-1 medications and metabolic health for people who want the reasoning, not just the conclusion — and publishes her own year on one of these drugs alongside it.
Keep reading
Supplements
The Best Supplements for GLP-1 Hair Loss
The shedding starts two to four months after the loss speeds up, which is why almost nobody connects the two. Seven supplements ranked — and one of them interferes with the blood test that rules out a heart attack.
Supplements
Best Bone Health Supplements on a GLP-1
Bone is the tissue nobody thinks about until a wrist breaks. Rapid weight loss reduces bone mineral density, the effect is largest in exactly the people most likely to be prescribed these drugs, and none of it produces a symptom until it does.
Tools
The Best GLP-1 Apps, Ranked
I scored every tracker I could get my hands on against seven criteria that matter specifically on a GLP-1 — not generic calorie counting. Here is the ranking, the rubric behind it, and where my first choice falls short.